FDA demands another trial for artificial skin
This article was originally published in Clinica
The FDA has told the maker of Dermagraft that it must start a new trial of the artificial skin in the US before it can be approved for diabetic foot ulcer patients. This is despite a conditional recommendation for approval from an advisory panel early this year. The move could set back sales of the skin for this application by as much as two years.
You may also be interested in...
India’s Sun Pharma has been denied leave to appeal against a US court decision rejecting the company’s bid for dismissal of a multi-district antitrust lawsuit.
Former Sandoz executive Hector Armando Kellum has admitted involvement in a US generic price-fixing conspiracy, the US Department of Justice has announced.
The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.